Hello, my name is Justin Taylor. I'm a physician at the University of Miami Sylvester Cancer Center. And at ASH we're presenting a study looking at the combination of a drug called eltanexer. It's an XPO1 inhibitor. It is not currently approved for use in patients, but it's being developed for myelodysplastic syndromes. We're looking at that drug in combination with venetoclax. This is a drug that is approved for patients with CLL, chronic lymphocytic leukemia, and acute myeloid leukemia or AML. It is also not yet approved in MDS. So this study was preliminary study looking at the preclinical combination of these two drugs for MDS patients eventually. Our findings were that this drug combination worked well together in something called Synergy, where both drugs, when combined together, are more potent than either drug alone. And we hope that this will soon be able to be used in patients in clinical trials. So for at the moment, this is not an approved therapy, but these drugs are currently being developed independently for patients with MDS. And one day this could be a promising combination for patients. My name is Sana Chaudhry. I am a PhD student in cancer biology at the University of Miami Miller School of Medicine. And I just presented an oral abstract on altered RNA export in SF3B1 mutants and how that leads to increased nuclear export inhibition. To summarize a little bit of the work, we were focused on myelodysplastic syndrome patients. These patients typically are given hypomethylating agents as their frontline treatment. But if those frontline treatments does not work for high-risk MDS, the survival is less than six months. So there is a major need for new therapeutics. And in the work that I presented, we saw that the combination of an Xp01 inhibitor with a Bcl2 inhibitor showed great efficacy in SF3B1 mutants MDS.
HealthTree • December 10, 2023